Life Science Buyers Identify Top Criteria to Support the New Generation of Trials
Edge Strategic Monitoring is Only RBM Solution to Address 95% of TransCelerate Technical Requirements and be Fully Compliant with ICH GCP E6 (R2) Requirements
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180213005857/en/
Medidata Clinical Cloud: One platform for Data Managers, Clinical Operations, Investigators, and Patients to accelerate the science and business of research.
- Optimize study design, feasibility and site grants utilizing benchmarking from 14,000+ studies
- Eliminate site escrow accounts with automatic investigator payments triggered by EDC
- Comply with ICH GCP E6 (R2) requirements with an end-to-end RBM suite
- Utilize master data management for study management
- Automate the collection of up to 76% of a trial master file
Edge is supported by the Rave
family of products, the most comprehensive data capture and management
solution, and is powered by
In a recent survey conducted by Medidata, life science decision makers and users identified the capabilities necessary to deliver the next generation of clinical trials, including EDC and risk based monitoring (RBM).
The top criteria for EDC are: price, (24%); integration (23%); robustness of features (18%); intuitiveness of software (18%); and database build speed (17%). Medidata’s Rave EDC is ranked as the top solution across all criteria.
For RBM the top criteria are: risk identification & evaluation (26%);
issue management & workflow (21%); reporting, analytics, visualization
(21%); targeted SDV (17%); and site visit management (15%). Edge
Strategic Monitoring is the only end-to-end comprehensive suite that
combines risk assessment and anomaly detection with centralized issue
management, enabling users to identify risks and document actions in
real-time while complying with ICH GCP E6 (R2) requirements.
Furthermore, Medidata addresses 95% of the 130 technical requirements
Join Medidata (Booth #800) at
Nina Pruitt| Speaker "The Rx for your Clinical Financial Management" | Tuesday, Feb 13, 12:05 p.m. Anthony Costello| Moderator "What Is Holding Back The Adoption Of eConsent" | Tuesday, Feb. 13at 4 p.m. Daniel O'Connell| Speaker "Think You’re ICH E6 Compliant? Show Me The Quality Tolerance Limits" | Wednesday, Feb. 14at 4:55 p.m.
Hrishikesh (Rishi) Karvir | Speaker "Applying Machine
Learning Frameworks to Improve Trial Outcomes" |
Thursday, Feb. 15at 9:55 a.m.
The double-blinded survey featured 100 life science respondents from the
Medidata's unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. The Medidata Clinical Cloud® connects patients, physicians and life sciences professionals. Companies on the Medidata platform are individually and collaboratively reinventing the way research is done to create smarter, more precise treatments. For more information: www.mdsol.com